Drug Profile
Research programme: oncolytic virus therapies and diagnostics - Oncolys BioPharma
Alternative Names: hTERTp-Ad5; OBP 405; OBP 502; Telomelysin-RGDLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator National Institute of Biomedical Innovation; Okayama University
- Developer Oncolys BioPharma
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Osteosarcoma; Solid tumours
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Solid-tumours in Japan (Intratumoural)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Solid-tumours(Combination therapy) in Japan (Intraperitoneal)
- 28 May 2022 No recent reports of development identified for preclinical development in Osteosarcoma(Combination therapy) in Japan (Injection)